Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells (IC50 :9.8 μM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 32.00 | |
10 mg | In stock | $ 52.00 | |
25 mg | In stock | $ 116.00 | |
50 mg | In stock | $ 198.00 | |
100 mg | In stock | $ 318.00 | |
200 mg | In stock | $ 473.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 44.00 |
Description | CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells (IC50 :9.8 μM). |
In vitro | CCG-100602 blocks the expression of MRTF-A/SRF-activated genes. CCG-100602 (3-30?μM) decreases the number of adherent hASC cells[1]. |
Molecular Weight | 478.82 |
Formula | C21H17ClF6N2O2 |
CAS No. | 1207113-88-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (208.85 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CCG-100602 1207113-88-9 Cell Cycle/Checkpoint GPCR/G Protein MAPK Rho Ras Inhibitor transcription inhibit serum myocardin nuclear SRF MRTF-A localization CCG100602 CCG 100602 inhibitor